Jaguar Health, Inc., a commercial-stage pharmaceutical company, focuses on developing prescription drugs for people and animals with gastrointestinal upset, specifically chronic debilitating diarrhea. The company is headquartered in San Francisco, California.
| Revenue (TTM) | $11.51M |
| Gross Profit (TTM) | $7.74M |
| EBITDA | $-43.20M |
| Operating Margin | -632.00% |
| Return on Equity | -411.60% |
| Return on Assets | -61.50% |
| Revenue/Share (TTM) | $172.73 |
| Book Value | $-99.20 |
| Price-to-Book | 1.62 |
| Price-to-Sales (TTM) | 0.14 |
| EV/Revenue | 4.163 |
| EV/EBITDA | -0.63 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -7.80% |
| Shares Outstanding | 513,940 |
| Float | 352,760 |
| % Insiders | 6.38% |
| % Institutions | 1.22% |
Volatility is currently expanding